Post Content
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) is among the 10 Fastest Growing NASDAQ Stocks to Buy.
On February 25, 2026, IDEAYA Biosciences, Inc. (NASDAQ:IDYA) announced that the first patient has been enrolled in its Phase 1 dose escalation and expansion trial evaluating IDE034, an investigational PTK7/B7H3 bispecific TOP1 ADC. The company plans to evaluate the safety, tolerability, and pharmacokinetics of IDE034 as a monotherapy in the Phase 1 study. It also intends to test combinations with agents targeting the DNA damage response pathway, including its proprietary PARG inhibitor IDE161. Dosing the first patient with IDE034 triggers a $5M milestone payment from Ideaya to Biocytogen under the companies’ option and license agreement.
On February 23, 2026, IDEAYA Biosciences announced the appointment of Theodora Ross to the newly created role of chief development officer. In this position, Ross will lead early clinical development for the company’s emerging oncology pipeline and help guide its long-term research and development strategy. Ross joins Ideaya from AbbVie, where she served as VP, head of early oncology R&D and site head for the Bay Area.
On February 17, 2026, IDEAYA Biosciences reported Q4 revenue of $10.88M, compared with consensus estimates of $5.95M. Collaboration revenue reflected performance obligations satisfied through December 31, 2025, related to research and development services recognized over time under the Servier exclusive license agreement for darovasertib. President and CEO Yujiro Hata said the company delivered “a strong quarter of clinical execution, clinical pipeline expansion and commercial readiness activities.” He cited highlights including completion of enrollment of 437 patients in the OptimUM-02 Phase 2/3 registrational trial, IND submissions for IDE034 and IDE574, and continued expansion of the company’s U.S. commercial organization ahead of upcoming topline progression-free survival results.
IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States.
While we acknowledge the potential of IDYA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 12 Best Tech Stocks that Beat Earnings Estimates and 40 Most Popular Stocks Among Hedge Funds Heading Into 2026
Disclosure: None. Follow Insider Monkey on Google News.